It was globally known this Monday, that Moderna had developed a brand new vaccine against the much feared coronavirus, with a surety of 94.5% efficiency. Director of Technical Operations and Quality of the pharmaceutical company Juan Andres, delivered a small interview to Antena 3 Noticias and had announced that the vaccine will be released in Spain during the first few weeks of 2021. They were on the way to sign a legal contract with the European Union and when that takes place officially, the approval of the European Medicines Agency will arrive, signalling them to begin supplying. They will be having two significant supply chains, one in Europe and one in the United States, for international community. This will happen as soon as possible, in the forthcoming weeks of 2021.
Results Yet To Be Published In Scientific Journals
When questioned on why the vaccine results haven’t yet been disclosed to even basic scientific journals, the manager informed that yesterday, when the afore mentioned medium in which the data was communicated to him, it was stated that the committee follows a strict clinical trial, with an external committee consisting of trained experts, as known on Sunday. Andres also confirmed that the data of the results are being delivered to the health officials who will then have to approve the product in order for it to be permitted to go on the market. By taking the side effects into consideration, volunteers (test subjects) have experienced grade 3 effects, which include injection site pain, pain in joints, body and headaches.
Very Legitimate Performance Than Any Other Vaccines and Is Highly Trustworthy
Recently, as he was going through the microphones of Cadena Ser, in which he explained the process of the distribution which will occur through Rovie in Spain and the Lonza Company from Switzerland, he was overjoyed with the legibility of the vaccine and admitted that he would put it on himself, “my wife, my children and my parents”, and that they can bet their lives on the vaccine. During the same station, he also confirmed that the vaccine is very much effective even amongst the most vulnerable of people. During the testing, he informed that the majority of the people who were represented in the trial were ones who were most vulnerable. Out of the 95 volunteers, 15 of them were over the age of 65. They also included “people of diverse ethnicities, so that it can be a fairly faithful representation of the social diversity.